Page No.: 2

## **Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims:**

1. (currently amended) A compound represented by Formula (I):

$$\begin{array}{c|c}
 & X^1 & X^2 & X^3 \\
\hline
 & X^5 & X^4 & X^4 & X^4
\end{array}$$

$$\begin{array}{c|c}
 & X^1 \\
 & X^2 \\
 & X^6 \\
 & X^4
\end{array}$$
(I)

or a pharmaceutically acceptable salt thereof, wherein  $X^1$ ,  $X^2$ ,  $X^4$ , and  $X^6$  are independently C, N, S or O;  $X^3$  is C; and  $X^5$  is are independently C or N; wherein at least one of  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$ ,  $X^5$ , and  $X^6$  is N; at most one of  $X^1$ ,  $X^2$ ,  $X^4$ , and  $X^6$  is S or O; Y is C0 4alkyl, aryl, or heteroaryl;  $R^1$  and  $R^2$  are independently halogen,  $C_{0.4}$ alkyl, or pyridyl; and  $n^1$  and  $n^2$  are independently 0 or 1.

- 2. (cancelled)
- 3. (currently amended) The compound according to Claim 2  $\underline{1}$ , or a pharmaceutically acceptable salt thereof, wherein  $X^1$ ,  $X^2$ ,  $X^3$ ,  $X^4$ , and  $X^6$  are C.

Page No.: 3

4. (currently amended) The compound according to Claim  $2\underline{1}$ , or a pharmaceutically acceptable salt thereof, wherein one of  $X^2, X^3$  and  $X^4$  is N, the other is remaining are C; and  $X^1$  and  $X^6$  are C.

- 5. (currently amended) The compound according to Claim  $2\underline{1}$ , or a pharmaceutically acceptable salt thereof, wherein two of  $X^2$ ,  $X^3$  and  $X^4$  are N, the remaining is C; and  $X^1$  and  $X^6$  are C.
- 6. (currently amended) The compound according to Claim 2  $\underline{1}$ , or a pharmaceutically acceptable salt thereof, wherein one of  $X^2$ ,  $X^3$  and  $X^4$  is N, the other is remaining are C;  $X^1$  is S; and  $X^6$  is C.
- 7. (currently amended) The compound according to Claim 2 1, or a pharmaceutically acceptable salt thereof, wherein one of  $X^2$ ,  $X^3$  and  $X^4$  is N, the other is remaining are C;  $X^1$  is S; and  $X^6$  is N.
  - 8. (cancelled)
  - 9. (cancelled)
  - 10. (cancelled)
  - 11. (currently amended) A compound represented by

Page No.: 4

or a pharmaceutically acceptable salt thereof.

12. (previously presented)A pharmaceutical composition comprising: a therapeutically effective amount of the compound according to claim 1, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

Page No.: 5

- 13. (cancelled)
- 14. (cancelled)
- 15. (currently amended) A method of treatment or prevention of pain comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.
- 16. (currently amended) A method of treatment or prevention of a pain disorder wherein said pain disorder is acute pain, persistent pain, chronic pain, inflammatory pain, or neuropathic pain, comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.
  - 17. (cancelled)
  - 18. (cancelled)
  - 19. (cancelled)
  - 20. (cancelled)
  - 21. (cancelled)
- 22. (currently amended) A method of treatment or prevention of neuropathic pain comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.
  - 23. (cancelled)
  - 24. (cancelled)
  - 25. (cancelled)
- 26. (currently amended) A method of treatment or prevention of inflammatory pain comprising the step of administering a therapeutically effective amount, or a prophylactically effective amount, of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.
  - 27. (cancelled)
  - 28. (cancelled)
- 29. (new) The compound of claim 1, optionally substituted with a substituent selected from halogen, C0-6alkyl, or heteroaryl.